Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2025-03-07 eCollection Date: 2025-03-01 DOI:10.1093/ofid/ofaf135

Charlotte-Paige Rolle, José R Arribas, Roberto Ortiz, Mark Underwood, Chris M Parry, Richard Grove, V Paul DiMondi, Bryn Jones, Michelle Kisare

引用次数: 0

Abstract

Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL). Clinical Trials Registration. NCT02831673/NCT02831764; NCT03945981.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.